Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ono Pharmaceutical Company, Ltd.

https://www.ono-pharma.com

Latest From Ono Pharmaceutical Company, Ltd.

Clear Eyes Production Problems Prestige Consumer Didn’t See Coming Leave Supply On Shelves ‘Spotty’

“Clear Eyes is a perfect example where we're dual-sourced and two facilities don't usually go down at the same time. This was just a quite an anomaly,” says CFO Christine Sacco, noting PCH works with more than 100 contract manufacturers.

OTC Drugs Supply Chain

J&J Continues Atopic Dermatitis Effort With Numab Deal

Johnson & Johnson, after several prior failed R&D attempts in AD, will pay Numab $1.25bn to acquire a subsidiary and its Phase II-ready bispecific antibody for key unmet needs in the disease.

M & A Business Strategies

Japan Reimburses Zolbetuximab, To Cut Price Of Imfinzi, Others

The first-in-class anti-CLDN 18.2 antibody zolbetuximab will face cost-effectiveness assessment in Japan in the near future, as the country applies stricter reimbursement pricing policies to gain transparency in expenditure through its healthcare reimbursement structure.

Japan Pricing Strategies

‘Mental Health, Beyond Medication’: Motif Targets Depression With Minimally Invasive DOT

Motif’s “pea-sized” Digitally programmable Over-brain Therapeutic (DOT) requires 20 minutes to implant and can be activated at home with a wearable to “lift the fog” for people with depression. Motif CEO Jacob Robinson believes data captured by brain-computer interfaces and continuous monitoring will eventually be able to identify key biomarkers that enable psychiatrists to head off mental health crises.

Behavioral Health Neurology
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Ono Pharma Korea Co., Ltd., Ono Venture Investment Fund I, L.P., Ono Venture Investment, Inc., Ono Pharma UK Ltd.
    • Ono Pharmaceutical Co., Ltd.
    • Ono Pharma Taiwan Co., Ltd.
UsernamePublicRestriction

Register